Franklin Resources
PLX icon

Franklin Resources’s Protalix BioTherapeutics PLX Stock Holding History

Franklin Resources’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.3K Buy
+41,314
New +$87.5K ﹤0.01% 2983
2024
Q3 		– Sell
-33,892
Closed -$39.7K – 3000
2024
Q2 		$39.7K Buy
33,892
+344
+1% +$406 ﹤0.01% 2747
2024
Q1 		$42.3K Hold
33,548
– – ﹤0.01% 2771
2023
Q4 		$59.7K Buy
+33,548
New +$52.2K ﹤0.01% 2514

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Franklin Resources's PLX Position: Q2 2026 in Review

Franklin Resources opened a new position in Protalix BioTherapeutics (PLX) in Q2 2026: 41,314 shares worth $96.3K. The stake represents ﹤0.01% of the portfolio and ranks #2983 among its holdings. This is a return to the name: Franklin Resources previously reported a position in PLX as recently as Q2 2024.

Franklin Resources first reported a position in PLX in Q4 2023 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • Franklin Resources held 41,314 shares of Protalix BioTherapeutics worth $96.3K as of Q2 2026.
  • Protalix BioTherapeutics was a new Franklin Resources position in Q2 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2983 holding.
  • Franklin Resources first reported a position in Protalix BioTherapeutics in Q4 2023 and has held it in 4 quarters since.
  • 102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.